Ascentage Pharma Group International Past Earnings Performance
Past criteria checks 0/6
Ascentage Pharma Group International has been growing earnings at an average annual rate of 10.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 73.2% per year.
Key information
10.4%
Earnings growth rate
29.5%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 73.2% |
| Return on equity | -46.4% |
| Net Margin | -39.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ascentage Pharma Group International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 903 | -360 | 378 | 841 |
| 31 Mar 24 | 563 | -643 | 377 | 774 |
| 31 Dec 23 | 222 | -926 | 376 | 707 |
| 30 Sep 23 | 239 | -902 | 363 | 709 |
| 30 Jun 23 | 257 | -879 | 349 | 712 |
| 31 Mar 23 | 233 | -881 | 339 | 727 |
| 31 Dec 22 | 210 | -883 | 328 | 743 |
| 30 Sep 22 | 160 | -848 | 299 | 767 |
| 30 Jun 22 | 111 | -812 | 270 | 790 |
| 31 Mar 22 | 69 | -797 | 231 | 778 |
| 31 Dec 21 | 28 | -782 | 191 | 766 |
| 30 Sep 21 | 25 | -759 | 167 | 699 |
| 30 Jun 21 | 23 | -735 | 143 | 631 |
| 31 Mar 21 | 18 | -706 | 137 | 598 |
| 31 Dec 20 | 12 | -678 | 130 | 565 |
| 30 Sep 20 | 14 | -922 | 146 | 540 |
| 30 Jun 20 | 15 | -1,167 | 162 | 516 |
| 31 Mar 20 | 15 | -1,324 | 162 | 490 |
| 31 Dec 19 | 15 | -1,481 | 162 | 464 |
| 30 Sep 19 | 11 | -1,171 | 133 | 418 |
| 30 Jun 19 | 7 | -862 | 104 | 372 |
| 31 Mar 19 | 7 | -604 | 97 | 311 |
| 31 Dec 18 | 7 | -345 | 90 | 250 |
| 31 Dec 17 | 6 | -119 | 26 | 119 |
| 31 Dec 16 | 8 | -108 | 22 | 103 |
Quality Earnings: 6855 is currently unprofitable.
Growing Profit Margin: 6855 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6855 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare 6855's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6855 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).
Return on Equity
High ROE: 6855 has a negative Return on Equity (-46.43%), as it is currently unprofitable.